H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)
BiologicalTwo injections at a 21-day interval (Days 1 and 22)
NCT Number: NCT00959465
The purpose of the study is to obtain immunogenicity and safety data at different dose levels of an investigational H1N1 pandemic influenza vaccine in healthy adults 18 years of age and older.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1 / Phase 2
Sanatorium Leech, Graz, Austria
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Two injections at a 21-day interval (Days 1 and 22)
Time frame: 42 days
Alachua Government Services, Inc.
Industry
An Open Label Phase 1/2 Study to Assess Immunogenicity and Safety of Different Dose Levels of H1N1 Pandemic Influenza Vaccine in Healthy Adults Aged 18 Years and Older
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00783926
Infections, Influenza
Wichita, Kansas, United States
View Trial DetailsNCT00976469
Infections, Influenza
Eferding, Upper Austria, Austria
View Trial DetailsNCT00950456
Infections, Influenza
Bludenz, Austria
View Trial DetailsNCT01053143
Infections, Influenza
Chandigarh, India
View Trial Details